Absci Corporation
- Open
- 9.00
- Day high
- 9.08
- Day low
- 8.71
- Prev close
- 9.04
- Volume
- 3.2M
- Mkt cap
- $1.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.2
- P/S
- 971.9
- Yield
- —
- Per share
- —
- ▲Insiders net buying $149K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions accumulating (13F)
Absci Corporation (ABSI) is a Healthcare company listed on NASDAQ. The stock is up 279% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4). Drillr has 1 published research article covering ABSI.
Absci Corporation (ABSI) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ABSI earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.19 | $-0.18 | +5.8% | $300000 | -67.4% |
| May 7, 2026 | $-0.20 | $-0.19 | +5.0% | $215000 | -84.5% |
| Mar 24, 2026 | $-0.16 | $-0.23 | -43.8% | $650000 | -54.2% |
| Nov 12, 2025 | $-0.19 | $-0.20 | -5.3% | $378000 | -72.6% |
| Aug 12, 2025 | $-0.19 | $-0.24 | -26.3% | $593000 | -88.5% |
| Mar 18, 2025 | $-0.22 | $-0.25 | -13.6% | $665000 | -86.3% |
| Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | $1M | -33.5% |
| Mar 21, 2024 | $-0.23 | $-0.25 | -8.7% | $338000 | -67.2% |
| Nov 14, 2023 | $-0.23 | $-0.24 | -4.3% | $744000 | -66.0% |
| Aug 14, 2023 | $-0.24 | $-0.27 | -12.5% | $3M | +38.2% |
| May 15, 2023 | $-0.24 | $-0.26 | -8.3% | $1M | -43.5% |
| Aug 11, 2022 | $-0.32 | $-0.32 | +0.0% | $1M | -38.2% |
ABSI insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Jonasson Zachariahofficer: CFO / CBO | Tax | 8,320 | $8.71 |
| Aug 7, 2026 | Somaratne Ransi Mudalinayakeofficer: CMO, Head of R&D | Grant | 383,000 | $7.93 |
| Aug 7, 2026 | Somaratne Ransi Mudalinayakeofficer: CMO, Head of R&D | Grant | 650,000 | $2.57 |
| Jul 6, 2026 | Szela Mary Tdirector | Buy | 12,900 | $11.54 |
| Jun 26, 2026 | McClain Seandirector, officer: Chief Executive Officer | Tax | 59,896 | $10.07 |
| Jun 15, 2026 | Szela Mary Tdirector | Grant | 8,400 | — |
| Jun 15, 2026 | Szela Mary Tdirector | Grant | 33,200 | $7.34 |
| Jun 11, 2026 | MCGINNIS KAREN Kdirector | Grant | 10,100 | — |
| Jun 11, 2026 | MCGINNIS KAREN Kdirector | Grant | 39,800 | $7.34 |
| Jun 8, 2026 | Rabinovitsj Daniel Adirector | Grant | 10,100 | — |
| Jun 8, 2026 | Rabinovitsj Daniel Adirector | Grant | 39,800 | $7.34 |
| Jun 8, 2026 | Sirosh Josephdirector | Grant | 10,100 | — |
| Jun 8, 2026 | Sirosh Josephdirector | Grant | 39,800 | $7.34 |
| Jun 8, 2026 | Szela Mary Tdirector | Grant | 10,100 | — |
| Jun 8, 2026 | Szela Mary Tdirector | Grant | 39,800 | $7.34 |
Source: ABSI SEC Form 4 filings, latest Sep 1, 2026. For informational purposes only — not investment advice.
See the full ABSI insider & 13F page →Absci Corporation company profile
Overview
Absci Corporation (NASDAQ:ABSI) is a biotechnology company founded in 2011 and headquartered in Vancouver, Washington. The company went public in July 2021 and operates as a drug and target discovery company that leverages artificial intelligence to create biologic drug candidates. Absci has developed an integrated drug creation platform that unifies traditional drug discovery and cell line development processes, enabling the design of antibodies for previously challenging or "undruggable" targets.
Business
Absci operates in the biotechnology sector, specifically focusing on drug discovery and development using artificial intelligence. The biotechnology industry involves the application of biological processes and organisms to develop pharmaceutical products, with companies typically spending years and hundreds of millions of dollars to bring a single drug to market. The company's core offering is its integrated drug creation platform, which combines AI-driven drug design with proprietary cell line development capabilities. This platform enables the creation of biologics - which are drugs derived from living organisms, typically proteins like antibodies that can target specific disease mechanisms. Unlike traditional small molecule drugs, biologics are complex, large molecules that often provide more targeted therapeutic effects but are significantly more difficult and expensive to develop. Absci's business model operates through two primary segments: 1. Partnership Revenue (estimated ~80-90% of current revenue): The company collaborates with pharmaceutical partners including AstraZeneca, Merck, Memorial Sloan Kettering Cancer Center, and others to discover and develop drug candidates using its AI platform. These partnerships typically involve upfront payments, research fees, milestone payments, and future royalties. 2. Internal Pipeline Development (estimated ~10-20% focus): Absci develops its own proprietary drug candidates, including ABS-101 (an anti-TL1A antibody for inflammatory diseases), ABS-201 (targeting androgenic alopecia/hair loss), and ABS-301 (an immuno-oncology program). These internal programs represent potential future revenue streams if successfully developed and commercialized. The company's AI platform specializes in designing antibodies that can target difficult-to-drug proteins, including G-protein-coupled receptors (GPCRs) and ion channels, which have historically been challenging for traditional drug discovery approaches.
Revenue model
Absci generates revenue through multiple streams within its biotechnology business model. The primary revenue source comes from partnership agreements with pharmaceutical companies, where Absci receives upfront payments, research fees, milestone payments upon achieving specific development goals, and future royalty payments if drugs reach commercialization. For example, the company's collaboration with AstraZeneca is worth $247 million in total potential value, including upfront payments and milestone-based compensation. The company's customers are primarily large pharmaceutical companies, mid-sized biotech firms, and academic medical centers who pay for access to Absci's AI-driven drug discovery capabilities. These partners value Absci's ability to design antibodies for targets that have been historically difficult to drug using conventional methods. Several factors influence Absci's profit margins and revenue potential. Positive margin drivers include the scalability of AI-based drug design, which can reduce the time and cost of early-stage drug discovery, and the company's ability to command premium pricing for targeting "undruggable" proteins. The platform's efficiency improvements could lead to higher success rates in drug development, making partnerships more valuable. Negative margin pressures include the high fixed costs of maintaining cutting-edge AI infrastructure and computational resources, the need for continuous investment in R&D to stay competitive, and the inherent risk that drug candidates may fail in clinical trials, potentially reducing future milestone and royalty payments. Additionally, increasing competition in AI-driven drug discovery could pressure partnership terms and pricing. The company's significant cash burn rate of approximately $72 million annually also indicates substantial ongoing operational costs that must be balanced against revenue generation.
Competitive moat
Absci's competitive moat appears moderate but potentially strengthening based on several key factors. The company's primary defensive position stems from its proprietary AI models and the data advantage accumulated through years of antibody design and optimization. The integration of drug discovery with cell line development in a single platform creates some operational efficiency that competitors would need time to replicate. The company's data moat is particularly relevant, as machine learning models improve with more training data, and Absci's partnerships provide continuous feedback loops to refine their algorithms. Their collaboration with technology companies like AMD for high-performance computing infrastructure also provides some technical advantages in processing speed and model sophistication. However, the moat faces significant challenges. The AI drug discovery space is becoming increasingly crowded, with both established pharmaceutical companies developing internal AI capabilities and numerous startups entering the market. Large technology companies like Google DeepMind and established biotech firms have substantial resources to develop competing platforms. Additionally, the core AI technologies underlying drug discovery are becoming more commoditized, with open-source models and cloud computing reducing barriers to entry. The company's ability to maintain its competitive position will likely depend on execution speed, the clinical success of its drug candidates, and its ability to demonstrate superior outcomes compared to traditional drug discovery methods. The partnership strategy provides some protection by creating switching costs for pharmaceutical partners, but these relationships are not exclusive and partners often work with multiple AI drug discovery companies simultaneously.
Risks & safety
Absci presents a moderate margin of safety with some concerning cash burn dynamics but reasonable liquidity position. • Liquidity and Solvency: Strong current ratio of 5.7x with $47 million in cash and short-term investments as of Q1 2025, down from $134 million reported in earnings calls. Total current assets of $156 million vs. current liabilities of $27 million provides adequate short-term coverage. • Cash Burn Risk: Significant concern with free cash flow burn of approximately $72 million annually. At current burn rate, existing cash provides runway into first half of 2027, but this assumes no acceleration in spending or clinical trial costs. • Debt Position: Minimal debt with debt-to-equity ratio of only 0.04, indicating low financial leverage and solvency risk. • Valuation Metrics: Trading at 1.6x book value and negative earnings multiples due to development stage. Enterprise value suggests market is pricing in substantial execution risk. • Other Considerations: Revenue remains minimal at $1.2 million quarterly, creating dependence on partnership deals and potential equity raises. Clinical trial outcomes for internal pipeline represent binary risk events that could significantly impact valuation.
Recent development
Over the past two years, Absci has executed a strategic pivot toward advancing its internal drug pipeline while maintaining its partnership-driven revenue model. The company has made significant progress in transitioning from purely a platform company to a drug developer with proprietary assets. Clinical Pipeline Advancement: The most significant development has been the progression of ABS-101, an anti-TL1A antibody for inflammatory diseases, into Phase I clinical trials in early 2025. This represents the company's first internally developed drug candidate to reach human testing. The company has also advanced ABS-201, targeting androgenic alopecia (hair loss), toward Phase I trials expected in early 2026, and continued development of ABS-301, an immuno-oncology program. Strategic Partnerships Expansion: Absci has significantly expanded its partnership portfolio, adding collaborations with Memorial Sloan Kettering Cancer Center for up to six oncology programs, partnerships with Owkin and Invetx, and maintaining existing relationships with AstraZeneca and Merck. The company has indicated expectations for additional large pharmaceutical partnerships in 2025. Technology Platform Enhancement: The company has invested heavily in its AI capabilities, including a collaboration with AMD for high-performance computing infrastructure. Management has emphasized improvements in their "naturalness" model for predicting antibody safety and reducing immunogenicity, positioning the platform for potential regulatory advantages as the FDA considers AI-based safety testing approaches. Capital Structure Optimization: Absci raised approximately $40 million through equity investments and established an at-the-market (ATM) facility, extending its cash runway into the first half of 2027. The company has also been selective in partnership terms, focusing on high-value collaborations rather than pursuing partnerships purely for revenue.
ABSI company profile · for informational purposes only — not investment advice.
Track ABSI with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free